Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

transcreation

Genesis Research Group A&P image

Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.

In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...

Genesis Research Group

regeneron headquarters

Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

MHRA approves Autolus Therapeutics’ Aucatzyl to treat acute lymphoblastic leukaemia

Approximately 765 new cases of the aggressive blood cancer are diagnosed in the UK every year

- PMLiVE

Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

- PMLiVE

Client/agency partnerships – a marriage of science and creativity

The first step in the partnership is selecting the right agency

- PMLiVE

Five things to know when engaging Gen Z patients

Learn more about Gen Z: who they are, where they can be reached and how they like to be engaged and find Say’s five tips to consider when engaging with...

Say Communications

- PMLiVE

Dermatology in Focus: Medscape Sponsors SDNP’s 2025 National Conference

Medscape Education is a proud sponsor of the 2025 SDNP National Conference, taking place from April 30 to May 3 at the Renaissance Esmeralda Resort and Spa in Indian Wells,...

Medscape Education

Reuters Pharma 2025

AI and away we go: key insights from Reuters Pharma 2025

AI is revolutionising the pharmaceutical industry, as highlighted at Reuters Pharma 2025, with transformative applications across marketing, drug discovery, and patient engagement, despite challenges in adoption, regulation, and data trust.

Cuttsy + Cuttsy

- PMLiVE

Merck KGaA expands rare tumour portfolio with $3.9bn SpringWorks acquisition

SpringWorks’ Gomekli was approved by the FDA earlier this year to treat patients with NF1

- PMLiVE

Roche to boost US footprint with $50bn investment over next five years

The commitment is aimed at bolstering the company’s pharmaceutical and diagnostics divisions

- PMLiVE

Pfizer’s sasanlimab improves event-free survival in phase 3 bladder cancer trial

As many as half of patients with high-risk NMIBC experience disease recurrence despite BCG treatment

- PMLiVE

Health misinformation: can pharma really have an impact?

False health narratives can erode trust, endanger lives and undermine medical progress

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links